• The Department of Emergency Medicine is nationally recognized for its innovative clinical and translational research, ranking 18th in National Institutes of Health (NIH) funding for academic emergency departments.


Highlighted Clinical Trials

RED CORAL: PETAL Repository of Electronic Data COVID-19 Observational Study

Status: Active
Period: March 2020 to June 2020

The epidemiology of patients hospitalized with severe COVID-19 has not been well defined, especially in the American context. There are significant knowledge gaps regarding demographics, clinical characteristics, trajectory of disease, timing of recovery, predictors of organ failure and death, resource utilization, and post-hospital outcomes. In response, the purpose of the RED CORAL study is to inform epidemiology and resource utilization through data collection and creation of a data repository.

The Prevention and Early Treatment of Acute Lung Injury (PETAL) Network is a consortium of academic and affiliated hospitals across the United States, funded by the NHLBI to conduct clinical trials in patients with or at risk for critical illness, including ARDS. Our Network’s goal is to improve outcomes of patients with acute and critical illness through research.

Study Aim
We will identify acute and critically ill patients with COVID-19 and collect detailed data from their hospital stay. We will contribute data to the WHO/ ISARIC COVID registry and to the scientific community in order to advance United States participation in studies of global epidemiology. We will use the data to increase understanding of the clinical course of COVID-19.

Study Population
RED CORAL will include adult patients with confirmed COVID-19 hospitalized at participating sites who have available clinical data. The study period will include patients who present for admission to study hospitals between March 1 and April 1, 2020.


Support Emergency Medicine Research

Research News

COVID-19 Patients with Respiratory Failure to Be Given NuvOx Pharma's Oxygen Therapeutic in Phase IIa Clinical Trial

Jarrod Mosier, MD, associate professor, UArizona Emergency Medicine and Internal Medicine and associate program director of the Critical Care Fellowship at Banner University Medical Center - Tucson, is a principal investigator of the U.S. sites in a Phase IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF).  

UArizona, State Expand COVID-19 Antibody Test Eligibility, Launch $7.7M Study on Immunity

A free statewide COVID-19 antibody testing program expands to 15 categories of essential workers at high risk of exposure, in concert with a $7.7 million UArizona study to better understand immunity.

UA-Led Initiative Doubles Survival Rates After Severe Traumatic Brain Injury

The implementation of a massive, statewide public health initiative led by University of Arizona researchers and involving 21,000 prehospital care patients has doubled the survival rate of severe traumatic brain injury victims and tripled the survival rate among those who were intubated.

Selected Recent Publications

Rinner GR, Watkins SA, Shirazi FMazda, et al. "Fatal abrin poisoning by injection." Clin Toxicol (Phila). 2020:1-3.
Acuña J, Situ-LaCasse EH, Patanwala AE, et al. "Identification of gender differences in ultrasound milestone assessments during emergency medicine residency training: a pilot study." Adv Med Educ Pract. 2019;10:141-145.
Smith G, Beger S, Vadeboncoeur T, et al. "Trends in overdose-related out-of-hospital cardiac arrest in Arizona." Resuscitation. 2019;134:122-126.
Lane AD, Berkman MR, Verbunker D, et al. "Retrospective Chart Analysis of Concussion Discharge Instructions in the Emergency Department." J Emerg Med. 2017.